Connect with us

Featured

Steady As She Mows

Daniel Chase

Published

on

stock_price_robin

Back in the 1980s, when life was simple and the music was, well, interesting, a movie was released predicting a time in the future where technology would one-day overtake its human creators.  “Terminator,” which starred former Governor of California Arnold Schwarzenegger, posited that in the near future, the very technological framework that we put in place to make our lives easier would rise against us, and initiate a program of genocide.

I apologize, ahead of time, for giving you any reason to think your Amazon Echo is out to get you, I watched far too much science-fiction films growing up. 

Nevertheless, as we embrace the ignorant bliss of automating our lives, tech startups are sprouting up left and right, utilizing artificial intelligence, and other SkyNet-esque technologies to offer products and services to consumers with their eyes on the future.

Whether we want it to or not, the future is pressing onward at an alarming rate. Slowly but surely, we’ve become a throw-away society with rodent-like attention spans, constantly looking for the next piece of technology we can purchase.

It’s a painful existence, and it would seem that living a life like this will result in never being fully satisfied, but if there’s one futuristic threshold worth breaking through, it’s embracing the world of automation. 

The ingenious minds responsible for some of the world’s most innovative tech companies have informed us, over the past few years, of their foray into projects related to self-driving vehicles, drone parcel delivery services, and, as it relates to today’s lesson, robotic lawnmowers. Back in 2016, Robin Autopilot was founded to take the pain out of maintaining a well-kept lawn, an issue that we can all get behind, right? 

“We were trying to find lawn care companies that were reliable, having to pay with cash or checks under doormats. I mean, we’re all tech guys from the 21st century, and it was hard to believe that there’s this $70 billion business that still operates the same way it did 30 years ago…”

Justin Crandall, co-Founder, Robin 

Robin’s automated mowing bots use a magnetometer rather than wireless or IR sensors, and cost roughly $100 – $150, but if that seems expensive, the Company claims that their electric-powered little fellows are eons away from traditional mowers, in terms of sustainability.

According to their website, one hour of mowing with a regular lawnmower emits “as much pollution as eleven hours in your car, and the mower spews 87 lbs. of greenhouse gases into the air each year.” Given that air pollution is one of the world’s most significant environmental health risks, Robin’s catering to consumers interested in living past their forties may serve them well as the Company continues to releases mowers. 

My only fault with Robin Autopilot is that there are millions of Americans who live in dwellings without lawns to maintain, resulting in the creation of a niche market perhaps so specific that it may hinder revenue. In recognition of this, Crandall, the Company’s co-Founder told TechCrunch that there are plenty of homes in need of Robin mowers. 

“In Texas over 90 percent of homes have a fenced in backyard, and even in places like Charlotte and Cleveland it’s roughly 25-30 percent, so technology like this is critical to adoption,” Crandall told me. “We generally dock the robots in the backyard for security. When it’s time to mow the front yard, the robots drive to the door we place in the fence. As it approaches the door, the robot drives over a sensor we place in the ground. That sensor unlocks the door to allow the mower access.”

Justin Crandall, co-Founder, Robin 

Continue Reading
Click to comment

Featured

Biotechnology Could Cure It All

Daniel Chase

Published

on

stock_price_biotech

Nearly two-thousand years ago, give or take several minutes, Hippocrates taught that human existence was centered around the four elements — earth, water, fire, and air — which in the human body was represented by the four basic humors: blood, phlegm, black bile, yellow bile. Hippocrates explained that each humor was located in a specific organ of the human body and each related to its own personality type — sanguine, phlegmatic, melancholic, and choleric.

‘Therefore, if someone was sick, Hippocrates taught that this indicated an imbalance in one of the four humors, so treatment included removing a given amount of the imbalanced humor through purging, bloodletting, etc. For those unfamiliar with bloodletting, it is the removal of some a patient’s blood which, in modern times, seems completely feasible, but back then this involved draining blood out of a person. 

Suffice to say that the medical field has moved forward since 460 BC, and recently, these advancements have occurred in the biotechnology industry. Though biotech is a relatively new field, it possesses great potential for the future of medicine. One of the more recent breakthroughs in biotech stems from something called pharmacogenomics, or the study of how genetics affect a person’s response to drugs. This new field combines the science of developing drug treatments and research conducted on human genetics and their functions. 

Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond

According to the U.S. National Library of Medicine, most drugs currently available on the market are branded as “one size fits all,”meaning that this specific treatment was created to cure a certain ailment for anyone who takes it. However, as scientists in the pharmacogenomics field are discovering, not everyone reacts the same to certain drugs.

For example, if two individuals are having an allergic reaction and both ingest an anti-histamine, it’s possible that it will help one person feel better, while causing adverse side-effects to the other person. By studying a person’s genetic coding, medical experts are better able to predict how a medication will effect a particular person. 

Ironically enough, as new technologies and inventive approaches to curing diseases come to light, medical researchers are discovering new diseases that seek to test all the progress we’ve made thus far. The practices of medicine have taken massive strides over the past few generations through the pioneering of biotechnology research and other incredible advancements, but regardless of these steps forward, it is up to companies in the healthcare industry to responsibly tend to the needs of their patients. 

Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) / (6PH.F) is a Canadian publicly traded company strategically poised to take advantage of lucrative business opportunities in the global healthcare industry. The Company is working to develop innovative healthcare approaches that combine human skill-based expertise with emerging technologies. What sets the Company apart from others in the field is that Premier is focused on developing their healthcare platform with a patient centric focus, looking to restore power back to the patients. For far too long, patients have been at the mercy of pharmaceutical companies who, by virtue of their capital, have maintained a chokehold on the price of drugs that patients need to stay healthy. 

In addition to rising treatments costs, as the global population increases, there are less primary physicians available for consumers looking to be cured. Through the use of Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) / (6PH.F) HealthVue app, patient can see their physician, access their charts & lab results, chat securely with clinical staff, reorder prescriptions and share remote health monitoring data with their doctor – all at their fingertips. The HealthVue app utilizes a virtual care platform designed to be easy to use and to improve a patient’s access to primary care. 

In addition these advanced healthcare solutions, the Company shared, in their most recent corporate update, that they plan on utilizing artificial intelligence to assist in virtually triaging the needs of their patients. Using their Healthvue app, the patient will answer a series of questions which will be relayed to the physician, along with a differential on possible diagnoses. This information will be pre-populated to the physicians charting system and will provide key patient information prior to the scheduled virtual visit, saving them a considerable amount of time and allowing more time for patient interaction. 

Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

Continue Reading

Featured

Stock Price Newsletter – February 21, 2019

Joe Samuel

Published

on

stock price newsletter

One Stock To Watch Ahead Of Healthcare Boom

See For Yourself


The Future Is Delicious

Details Here


Here’s What You Missed 2/20/19

Get The Full Story Here


Continue Reading

Featured

Mueller Investigation Is Almost Ready

Daniel Chase

Published

on

stock_price_mueller

A half-witted, know-nothing playwright by the name of William Shakespeare once wrote that “these violent delights have violent ends.” The line, taken from Shakespeare’s Romeo and Juliet, also featured in Westworld, depicts a scene in which Friar Laurence cautions Romeo into falling for Juliet because his love may catalyze his own violent end. I attribute the words of Shakespeare to the current predicament facing President Donald Trump and his administration. In the two or so years since Trump took office, special counsel Robert Mueller has worked without end to investigate whether the Trump administration colluded in any way, shape, or form, with Russia during the 2016 presidential election. 

After countless subpoenas and inducements of former Trump associates and administration members, sources indicate that Mueller’s long nights away from the family could soon be over. Towards that end of January, Roger Stone, a former associate of Donald Trump before he became president, was indicted on charges of seeking stolen emails from WikiLeaks that could damage Trump’s opponents during the 2016 presidential election season. 

Per the official language of the indictment:

“…After the 2016 U.S. presidential election, the U.S. House of Representatives Permanent Select Committee on Intelligence, the U.S. Senate Select Committee on Intelligence, and the Federal Bureau of Investigation opened or announced their respective investigations into Russian interference in the 20126 U.S. presidential election…Stone took steps to obstruct these investigations….He made false statements to the HPSCI about his interactions regarding WikiLeaks, and falsely denied possessing records that contained evidence…”

-Robert Stone indictment 

The indictment went on to explain that Stone attempted to persuade a witness to provide false testimony and withheld pertinent information from federal investigators. According to several sources, Stone was arrested by the FBI Friday morning while drinking his morning coffee at his home in Florida. Stone’s attorney immediately attempted to defuse any public sentiment stirring up connecting Stone to special counsel Mueller’s investigation, suggesting that Stone’s indictment “focuses on allegedly false statements…made to Congress,” and has nothing to do with Russian collusion. 

According to CNN, Attorney General Bill Barr is limbering up in preparation to announce as early as next week the completion of Robert Mueller’s investigation, “with plans for Barr to submit to Congress soon after a summary” of the confidential report is prepared. Interestingly enough, though the details of the report concern both the American people and its presiding government, under special counsel regulations, Mueller must submit his “report” to the attorney general and the law doesn’t require this document to be shared with anyone.

Barr is under no formal obligation to publicly share the report, but I can already assume that members of the Democratic leadership will be banging on his office door until he throws them a bone. 

The question on everyone’s mind is, what Mueller discovered in his lengthy investigation. Mueller was appointed to the case on May 17, 2017, and in years following this date, Mueller has had his hands full. Early last week, Mueller’s office filed its sentencing memorandum against Paul Manafort, Trump’s former campaign manager, who will be sentenced next month in federal district court in the District of Columbia. 

“For a decade, Manafort repeatedly violated the law. Considering only the crimes charged in this district, they make plain that Manafort chose to engage in a sophisticated scheme to hide millions of dollars from United States authorities. The sentence in this case must take into account the gravity of this conduct, and serve to both specifically deter Manafort and those who would commit a similar series of crimes.”

sentencing memo from Robert Mueller

As for the findings of Mueller’s investigation, we will have to wait and see how Attorney General Barr chooses to go about sharing the report, if he ends up sharing the information at all. The information could disturb the Trump presidency and possibly give Democrats grounds for introducing articles of impeachment. 

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com